×
S&P 500   3,818.83 (-0.07%)
DOW   31,029.31 (+0.27%)
QQQ   283.86 (+0.11%)
AAPL   139.10 (+1.21%)
MSFT   260.00 (+1.37%)
META   163.83 (+1.96%)
GOOGL   2,233.00 (-0.32%)
AMZN   108.82 (+1.32%)
TSLA   685.35 (-1.81%)
NVDA   155.40 (-2.77%)
NIO   21.87 (-2.19%)
BABA   116.16 (-0.51%)
AMD   77.99 (-3.45%)
MU   56.05 (-3.13%)
CGC   3.50 (-3.05%)
T   20.95 (+1.65%)
GE   63.69 (-3.32%)
F   11.52 (-2.46%)
DIS   95.74 (-0.19%)
AMC   13.63 (+1.87%)
PFE   50.94 (+0.55%)
PYPL   71.54 (-0.39%)
NFLX   178.50 (-0.61%)
S&P 500   3,818.83 (-0.07%)
DOW   31,029.31 (+0.27%)
QQQ   283.86 (+0.11%)
AAPL   139.10 (+1.21%)
MSFT   260.00 (+1.37%)
META   163.83 (+1.96%)
GOOGL   2,233.00 (-0.32%)
AMZN   108.82 (+1.32%)
TSLA   685.35 (-1.81%)
NVDA   155.40 (-2.77%)
NIO   21.87 (-2.19%)
BABA   116.16 (-0.51%)
AMD   77.99 (-3.45%)
MU   56.05 (-3.13%)
CGC   3.50 (-3.05%)
T   20.95 (+1.65%)
GE   63.69 (-3.32%)
F   11.52 (-2.46%)
DIS   95.74 (-0.19%)
AMC   13.63 (+1.87%)
PFE   50.94 (+0.55%)
PYPL   71.54 (-0.39%)
NFLX   178.50 (-0.61%)
S&P 500   3,818.83 (-0.07%)
DOW   31,029.31 (+0.27%)
QQQ   283.86 (+0.11%)
AAPL   139.10 (+1.21%)
MSFT   260.00 (+1.37%)
META   163.83 (+1.96%)
GOOGL   2,233.00 (-0.32%)
AMZN   108.82 (+1.32%)
TSLA   685.35 (-1.81%)
NVDA   155.40 (-2.77%)
NIO   21.87 (-2.19%)
BABA   116.16 (-0.51%)
AMD   77.99 (-3.45%)
MU   56.05 (-3.13%)
CGC   3.50 (-3.05%)
T   20.95 (+1.65%)
GE   63.69 (-3.32%)
F   11.52 (-2.46%)
DIS   95.74 (-0.19%)
AMC   13.63 (+1.87%)
PFE   50.94 (+0.55%)
PYPL   71.54 (-0.39%)
NFLX   178.50 (-0.61%)
S&P 500   3,818.83 (-0.07%)
DOW   31,029.31 (+0.27%)
QQQ   283.86 (+0.11%)
AAPL   139.10 (+1.21%)
MSFT   260.00 (+1.37%)
META   163.83 (+1.96%)
GOOGL   2,233.00 (-0.32%)
AMZN   108.82 (+1.32%)
TSLA   685.35 (-1.81%)
NVDA   155.40 (-2.77%)
NIO   21.87 (-2.19%)
BABA   116.16 (-0.51%)
AMD   77.99 (-3.45%)
MU   56.05 (-3.13%)
CGC   3.50 (-3.05%)
T   20.95 (+1.65%)
GE   63.69 (-3.32%)
F   11.52 (-2.46%)
DIS   95.74 (-0.19%)
AMC   13.63 (+1.87%)
PFE   50.94 (+0.55%)
PYPL   71.54 (-0.39%)
NFLX   178.50 (-0.61%)
NASDAQ:NVCT

Nuvectis Pharma Stock Forecast, Price & News

$11.78
-0.33 (-2.73%)
(As of 06/29/2022 03:59 PM ET)
Add
Compare
Today's Range
$11.05
$11.98
50-Day Range
$9.04
$20.44
52-Week Range
$3.08
$20.92
Volume
505 shs
Average Volume
952,432 shs
Market Capitalization
$149.82 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$21.00
30 days | 90 days | 365 days | Advanced Chart

Receive NVCT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nuvectis Pharma and its competitors with MarketBeat's FREE daily newsletter.

NVCT Stock Forecast (MarketRank)

Overall MarketRank

2.03 out of 5 stars

Medical Sector

569th out of 1,433 stocks

Pharmaceutical Preparations Industry

253rd out of 685 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
Nuvectis Pharma logo

About Nuvectis Pharma (NASDAQ:NVCT)

Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src and YES1 kinases. The company was incorporated in 2020 and is based in Fort Lee, New Jersey.

NVCT Stock News Headlines

Nuvectis Pharma, Inc. Common Stock (NVCT)
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:NVCT
Fax
N/A
Employees
8
Year Founded
N/A

Company Calendar

Last Earnings
5/10/2022
Today
6/29/2022
Next Earnings (Estimated)
8/09/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$21.00
High Stock Price Forecast
$21.00
Low Stock Price Forecast
$21.00
Forecasted Upside/Downside
+78.3%
Consensus Rating
Buy
Rating Score (0-4)
3
Research Coverage
2 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
($1.16) per share

Miscellaneous

Free Float
N/A
Market Cap
$149.82 million
Optionable
Not Optionable
Beta
N/A














Nuvectis Pharma Frequently Asked Questions

Should I buy or sell Nuvectis Pharma stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Nuvectis Pharma in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Nuvectis Pharma stock.
View analyst ratings for Nuvectis Pharma
or view top-rated stocks.

What is Nuvectis Pharma's stock price forecast for 2022?

2 equities research analysts have issued 1-year price targets for Nuvectis Pharma's shares. Their NVCT stock forecasts range from $21.00 to $21.00. On average, they expect Nuvectis Pharma's stock price to reach $21.00 in the next year. This suggests a possible upside of 78.3% from the stock's current price.
View analysts' price targets for Nuvectis Pharma
or view top-rated stocks among Wall Street analysts.

How has Nuvectis Pharma's stock price performed in 2022?

Nuvectis Pharma's stock was trading at $3.25 at the beginning of 2022. Since then, NVCT stock has increased by 262.5% and is now trading at $11.78.
View the best growth stocks for 2022 here
.

When is Nuvectis Pharma's next earnings date?

Nuvectis Pharma is scheduled to release its next quarterly earnings announcement on Tuesday, August 9th 2022.
View our earnings forecast for Nuvectis Pharma
.

How were Nuvectis Pharma's earnings last quarter?

Nuvectis Pharma, Inc. (NASDAQ:NVCT) released its earnings results on Tuesday, May, 10th. The company reported ($0.32) earnings per share for the quarter, missing analysts' consensus estimates of ($0.23) by $0.09.
View Nuvectis Pharma's earnings history
.

Who are Nuvectis Pharma's key executives?

Nuvectis Pharma's management team includes the following people:
  • Mr. Ron Bentsur M.B.A., Co-Founder, Chairman, CEO & Pres (Age 56)
  • Dr. Enrique Poradosu Ph.D., Co-Founder, Exec. VP and Chief Scientific & Bus. Officer (Age 55, Pay $27.08k)
  • Mr. Shay Shemesh, Co-Founder, EVP, Chief Devel. & Operations Officer (Age 38, Pay $27.08k)
  • Mr. Michael Carson CPA, Interim Chief Financial Officer (Age 46)

When did Nuvectis Pharma IPO?

(NVCT) raised $19 million in an IPO on Friday, February 4th 2022. The company issued 3,200,000 shares at $5.00-$7.00 per share.

What is Nuvectis Pharma's stock symbol?

Nuvectis Pharma trades on the NASDAQ under the ticker symbol "NVCT."

When does Nuvectis Pharma's lock-up period expire?

Nuvectis Pharma's lock-up period expires on Wednesday, August 3rd. Nuvectis Pharma had issued 3,200,000 shares in its initial public offering on February 4th. The total size of the offering was $16,000,000 based on an initial share price of $5.00. Shares of the company owned by company insiders and major shareholders will be eligible for trade following the expiration of the lock-up period.

Who are Nuvectis Pharma's major shareholders?

Nuvectis Pharma's stock is owned by a number of institutional and retail investors. Top institutional investors include Ronit Capital LLP (4.32%), Virtu Financial LLC (0.09%) and BlackRock Inc. (0.06%). Company insiders that own Nuvectis Pharma stock include Kenneth Hoberman, Ron Bentsur and Shay Shemesh.
View institutional ownership trends for Nuvectis Pharma
.

Which institutional investors are buying Nuvectis Pharma stock?

NVCT stock was acquired by a variety of institutional investors in the last quarter, including Ronit Capital LLP, Virtu Financial LLC, and BlackRock Inc.. Company insiders that have bought Nuvectis Pharma stock in the last two years include Kenneth Hoberman, Ron Bentsur, and Shay Shemesh.
View insider buying and selling activity for Nuvectis Pharma
or or view top insider-buying stocks.

How do I buy shares of Nuvectis Pharma?

Shares of NVCT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Nuvectis Pharma's stock price today?

One share of NVCT stock can currently be purchased for approximately $11.78.

How much money does Nuvectis Pharma make?

Nuvectis Pharma (NASDAQ:NVCT) has a market capitalization of $149.82 million.

How many employees does Nuvectis Pharma have?

Nuvectis Pharma employs 8 workers across the globe.

How can I contact Nuvectis Pharma?

The official website for Nuvectis Pharma is www.nuvectis.com. The company can be reached via phone at 201-614-3150.

This page (NASDAQ:NVCT) was last updated on 6/29/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.